FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132395786> ?p ?o ?g. }

• W3132395786 endingPage "185" @default.
• W3132395786 startingPage "181" @default.
• W3132395786 abstract "Nearly 10% of patients with high-risk early-stage melanoma will develop satellite or in-transit metastases (ITM), classified as stage III disease similar to lymph node metastases. The pivotal registration trials of the CTLA-4 antibody ipilimumab, and the PD-1 antibodies nivolumab and pembrolizumab, also included patients with unresectable stage III disease. However, there has been no analysis of patients with ITM, and anecdotal retrospective small series have indicated a potential lesser effect. This study aimed to identify patients with unresectable ITM within the randomized trials, and to determine response, progression-free survival and overall survival. The pivotal phase III randomized intervention trials that included melanoma patients with ITM, with or without nodal metastasis, and were treated with ipilimumab, nivolumab or pembrolizumab was identified. The datasets from each trial were then searched to identify the specific details of the investigated patient population for a pooled analysis. The primary endpoint was complete response rate. Seven trials that included stage III patients, and with accessible datasets, were identified. There was a total of 4711 patients, however, no patients with ITM could be identified, as this data was not captured by the case report forms. Evidence from prospective clinical trials on the use of immunotherapy in patients with ITM is lacking. We recommend pooling data from multiple institutions to examine efficacy of available drug therapies in this patient population, but more importantly, prospective clinical trials of locoregional treatments with or without systemic drug therapies are required." @default.
• W3132395786 created "2021-03-01" @default.
• W3132395786 creator A5014354451 @default.
• W3132395786 creator A5019573174 @default.
• W3132395786 creator A5026967523 @default.
• W3132395786 creator A5029398339 @default.
• W3132395786 creator A5056132643 @default.
• W3132395786 creator A5062124149 @default.
• W3132395786 creator A5071577704 @default.
• W3132395786 creator A5076054848 @default.
• W3132395786 creator A5084967339 @default.
• W3132395786 creator A5091860403 @default.
• W3132395786 date "2021-02-18" @default.
• W3132395786 modified "2023-09-30" @default.
• W3132395786 title "The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials" @default.
• W3132395786 cites W2019607817 @default.
• W3132395786 cites W2038030122 @default.
• W3132395786 cites W2041947339 @default.
• W3132395786 cites W2069438330 @default.
• W3132395786 cites W2097995306 @default.
• W3132395786 cites W2112121482 @default.
• W3132395786 cites W2132795479 @default.
• W3132395786 cites W2152897456 @default.
• W3132395786 cites W2320835924 @default.
• W3132395786 cites W2580064732 @default.
• W3132395786 cites W2587644640 @default.
• W3132395786 cites W2603690292 @default.
• W3132395786 cites W2740393355 @default.
• W3132395786 cites W2747107882 @default.
• W3132395786 cites W2750781282 @default.
• W3132395786 cites W2752227448 @default.
• W3132395786 cites W2797309423 @default.
• W3132395786 cites W2896253897 @default.
• W3132395786 cites W2903162576 @default.
• W3132395786 cites W2913421913 @default.
• W3132395786 cites W2914448678 @default.
• W3132395786 cites W2924571947 @default.
• W3132395786 cites W2947338182 @default.
• W3132395786 cites W2947765148 @default.
• W3132395786 cites W2948662515 @default.
• W3132395786 cites W2949375297 @default.
• W3132395786 cites W2963476376 @default.
• W3132395786 cites W2991047437 @default.
• W3132395786 cites W3008406199 @default.
• W3132395786 cites W3013646646 @default.
• W3132395786 cites W3023666666 @default.
• W3132395786 cites W3043703771 @default.
• W3132395786 cites W4248728884 @default.
• W3132395786 cites W4256631179 @default.
• W3132395786 cites W4379373389 @default.
• W3132395786 doi "https://doi.org/10.1097/cmr.0000000000000719" @default.
• W3132395786 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33625104" @default.
• W3132395786 hasPublicationYear "2021" @default.
• W3132395786 type Work @default.
• W3132395786 sameAs 3132395786 @default.
• W3132395786 citedByCount "11" @default.
• W3132395786 countsByYear W31323957862021 @default.
• W3132395786 countsByYear W31323957862022 @default.
• W3132395786 countsByYear W31323957862023 @default.
• W3132395786 crossrefType "journal-article" @default.
• W3132395786 hasAuthorship W3132395786A5014354451 @default.
• W3132395786 hasAuthorship W3132395786A5019573174 @default.
• W3132395786 hasAuthorship W3132395786A5026967523 @default.
• W3132395786 hasAuthorship W3132395786A5029398339 @default.
• W3132395786 hasAuthorship W3132395786A5056132643 @default.
• W3132395786 hasAuthorship W3132395786A5062124149 @default.
• W3132395786 hasAuthorship W3132395786A5071577704 @default.
• W3132395786 hasAuthorship W3132395786A5076054848 @default.
• W3132395786 hasAuthorship W3132395786A5084967339 @default.
• W3132395786 hasAuthorship W3132395786A5091860403 @default.
• W3132395786 hasConcept C121608353 @default.
• W3132395786 hasConcept C126322002 @default.
• W3132395786 hasConcept C143998085 @default.
• W3132395786 hasConcept C168563851 @default.
• W3132395786 hasConcept C203092338 @default.
• W3132395786 hasConcept C2777658100 @default.
• W3132395786 hasConcept C2777701055 @default.
• W3132395786 hasConcept C2780030458 @default.
• W3132395786 hasConcept C2780057760 @default.
• W3132395786 hasConcept C2781433595 @default.
• W3132395786 hasConcept C2908647359 @default.
• W3132395786 hasConcept C502942594 @default.
• W3132395786 hasConcept C535046627 @default.
• W3132395786 hasConcept C71924100 @default.
• W3132395786 hasConcept C99454951 @default.
• W3132395786 hasConceptScore W3132395786C121608353 @default.
• W3132395786 hasConceptScore W3132395786C126322002 @default.
• W3132395786 hasConceptScore W3132395786C143998085 @default.
• W3132395786 hasConceptScore W3132395786C168563851 @default.
• W3132395786 hasConceptScore W3132395786C203092338 @default.
• W3132395786 hasConceptScore W3132395786C2777658100 @default.
• W3132395786 hasConceptScore W3132395786C2777701055 @default.
• W3132395786 hasConceptScore W3132395786C2780030458 @default.
• W3132395786 hasConceptScore W3132395786C2780057760 @default.
• W3132395786 hasConceptScore W3132395786C2781433595 @default.
• W3132395786 hasConceptScore W3132395786C2908647359 @default.
• W3132395786 hasConceptScore W3132395786C502942594 @default.
• W3132395786 hasConceptScore W3132395786C535046627 @default.

• next